Dr. Oneto is a board-certified gastroenterologist in private practice, affiliated with NYU Langone Health. She is passionate about digestive health and recognizes the significant impact of lifestyle choices on digestive health. She encourages patients to prioritize sleep, diet, and physical activity as part of their well-being journey.

Dr. Oneto focuses on a wide range of digestive conditions, including:

  • Colon Cancer Prevention: Empowering patients with knowledge and tools for prevention and early detection.
  • Inflammatory Bowel Disease (IBD): Providing comprehensive care for patients with Crohn’s disease and ulcerative colitis.
  • Irritable Bowel Syndrome (IBS) & Small Intestinal Bacterial Overgrowth (SIBO): Offering effective treatment options to improve quality of life.
  • GERD & Peptic Ulcer Disease: Treating heartburn, reflux, and ulcers caused by excess stomach acid or H. Pylori infection.
  • Eosinophilic Esophagitis (EoE): Managing inflammation of the esophagus caused by an allergic reaction.

Beyond patient care, Dr. Oneto is actively involved in research. As co-director of Manhattan Clinical Research, she leads clinical studies on the gut microbiome, IBD, celiac disease, and other gastrointestinal conditions. Her passion for research helps translate cutting-edge science into real-world improvements for patients.

Dr. Oneto is fluent in Spanish. She graduated with a degree in medicine and surgery from the Universidad de Valparaiso. She later on did her residency in Internal medicine at the Cabrini Medical Center, Mount Sinai School of Medicine , where she also served as Chief resident. She completed her fellowship in gastroenterology at Montefire Medical Center, Albert Einstein College of Medicine.

Publications

Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial

Aroniadis OC, Brandt LJ,Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, Kassam Z, Sadovsky RG, Elliott RJ, Budree S, Kim M, Keller MJ. 

Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685. doi: 10.1016/S2468-1253(19)30198-0. Epub 2019 Jul 17. PMID: 31326345.

Prescription Microbiome Therapeutic for Recurrent Clostridioides difficile Infection: Fecal Microbiota Live-jslm.

Oneto C, Khanna S. 

Am J Gastroenterol. 2024 Jan 1;119(1S):S16-S21. doi: 10.14309/ajg.0000000000002577.
PMID: 38153221 

Concise Commentary: Treatment of Recurrent C. difficile Infection: A New Take on the Fecal-Oral Route

Oneto C, Feuerstadt P.

Dig Dis Sci. 2019 Jun;64(6):1679. doi: 10.1007/s10620-019-05498-6. PMID: 30762209.

Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings

Dogra S,Oneto C, Sherman A, Varughese R, Yuen A, Sherman I, Cohen A, Luo Y, Chen LA. 

J Clin Gastroenterol. 2022 Oct 14. doi: 10.1097/MCG.0000000000001778. Epub ahead of print. PMID: 36227005.

Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey

Lurienne L, Bandinelli PA, Galvain T, Coursel CA,Oneto C, Feuerstadt P.

J Patient Rep Outcomes. 2020 Feb 19;4(1):14. doi: 10.1186/s41687-020-0179-1. PMID: 32076853; PMCID: PMC7031450.

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL,Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L; ECOSPOR IV Investigators. 

JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/ jamanetworkopen.2022.55758. PMID: 36780159; PMCID: PMC9926325.

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial

Garey KW, Jo J, Gonzales-Luna AJ, Lapin B, Deshpande A, Wang E, Hasson B, Pham SV, Huang SP, Reese PR, Wu H, Hohmann E, Feuerstadt P,Oneto C, Berenson CS, Lee C, McGovern B, vonMoltke L.

JAMA Netw Open. 2023 Jan 3;6(1):e2253570. doi: 10.1001/jamanetworkopen.2022.53570. Erratum in: JAMA Netw Open. 2023 Feb 1;6(2):e234174. PMID: 36716031; PMCID: PMC9887497.

Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection

Feuerstadt P,Oneto C, Tillotson G, Van Hise NW.

Patient Prefer Adherence. 2023 Aug 30;17:2153-2159. doi: 10.2147/PPA.S415681. eCollection 2023.
PMID: 37667688 

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic

Berenson CS, Lashner B, Korman LY, Hohmann E, Deshpande A, Louie TJ, Sims M, Pardi D, Kraft CS, Wang EEL, Cohen SH, Feuerstadt P,Oneto C, Misra B, Pullman J, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Lee CH.

Clin Infect Dis. 2023 Nov 30;77(11):1504-1510. doi: 10.1093/cid/ciad448.
PMID: 37539715